Gothenburg, May 25, 2026 - Elicera Therapeutics AB (publ) ("Elicera"), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with bystander immune activating properties using the company's commercially available platform iTANK, today announced that the Company has now received approval for the final reporting to the European Innovation Council Accelerator Programme for the CARMA study, and that a final payment has also been approved.
The final payment amounts to approximately EUR 130,000, bringing the total amount received by the Company from the EIC Accelerator Fund to approximately EUR 2,380,000 to support the ongoing Phase I/IIa CARMA study with Elicera's CAR T-cell therapy ELC-301.
The CARMA study is a Phase I/IIa clinical trial evaluating the safety and preliminary efficacy of ELC-301 (a CD20-targeted CAR T-cell therapy armed with the iTANK platform) in patients with relapsed or refractory B-cell lymphoma. The grant from the EIC Accelerator Fund has been of great importance in financing the study in parallel with other funding sources.
This approval marks a successful conclusion of the formal reporting process to the European Commission/EIC and confirms that all reporting requirements have been fulfilled.
Relevance for Elicera
· The grant has strengthened the Company's financial position and enabled continued progress in the CARMA study, thereby delaying the need for additional capital.
· The approved final reporting strengthens Elicera's track record vis-à-vis both public funders and investors.
· The results from the CARMA study, which have shown promising clinical data so far, have been reported within the framework of the project.